Type 1 diabetes Type 1 diabetes
Conditions
Interventions
None listed
Sponsors
Miyatsuka Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: More than 18 years old patients with a diagnosis of type 1 diabetes and type 1 diabetes caused by immune checkpoint inhibitors from the date of approval by the hospital director to March 31, 2025, have been started treatment at the Department of Endocrinology and Metabolism, Kitasato University Hospital or the Department of Endocrinology and Metabolism, Kitasato University Medical Center, understand the purpose of this study and are given consent. More than 18 years old normal glucose-tolerant subjects (volunteers) understand the purpose of the study and are given their consent. Volunteers will be recruited by posting posters on the bulletin board in the School of Medicine.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of plasma peptides specific to patients with type 1 diabetes and patients with type 1 diabetes induced by immune checkpoint inhibitors. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of plasma peptides at study entry and 12-24 weeks after entry in patients with type 1 diabetes and type 1 diabetes induced by immune checkpoint inhibitors. | — |
Contacts
Public ContactHaremaru Kubo
Kitasato university hospital
Outcome results
None listed